Tour de Table Mid-term Meeting 3rd June 2015

QEHB Queen Elizabeth Hospital Birmingham, UK Large Teaching Hospital >1200 beds Dialysis population >1000 With 800+ patients on HD 400 VA procedures (surgical) 500+ IR procedures

QEHB Research interests: ReDVA ESR Vascular access MER All aspects of renal diseases Basic science Renal research Trials (>20 ongoing) Vascular access Completed CTiMP on GTN in AVFs 200 patients recruited Multiple other trials in process ReDVA ESR Zaib Khawaja Julien Alshakarchi MER Nick Inston Predominately WP2/3 with Guerbet, Paris

Guerbet Group Organization Marie-Claire Janailhac-Fritsch, Chairman of the Board of Directors Yves L’Epine, Chief Executive Officer Marie-Claire Taine, VP Commercial Jean-Sébastien Raynaud Pierre Desché, VP Development, Medical & Regulatory Affairs Eric Lancelot

Interventional Radiology and Theranostics (IRT) Guerbet Four growth drivers Interventional Radiology and Theranostics (IRT) X-ray MRI Medical Devices (MD) Xenetix® Telebrix® Hexabrix® … Dotarem® Artirem® … Lipiodol® Patent Blue® … FlowSens® Manyfill® Secufill® … 1 2 3 4

Guerbet Principle stages of development 1901: Marcel Guerbet discovered the first iodinated contrast medium, Lipiodol 1926: André Guerbet founded Laboratoires Guerbet 1989: Dotarem launch for MRI imaging 1995: Xenetix launch for X-ray imaging 2006: ScanBag by Xenetix launch with its bag injector (SBI by Medex) 2010: Launch of the Fill range of medical devices by Medex 2011: Yves L’Epine appointed CEO 2013: Dotarem launch in the US 2014: Launch of FlowSens, new generation injection solution in CT imaging

Michael Walsh PhD ULIM PI WP5 Leader

Team 2014/2015/2016 Michael Walsh PhD – ULIM PI – WP5 Leader - MER Secondee David Newport PhD – MER Secondee 2014/2015 Stephen Broderick PhD – ER Secondee Leonard Browne PhD – ESR Secondee 2015/2016 Sinead Morley BE – ESR Secondee Connor Cunnane BE – ESR Secondee Recruitment 2015/2016 ER – Numerical Modelling of AV access hemodynamics ER – Experimental Modelling of AV access hemodynamics

Vascular Flow Technologies (VFT) has grown from a tiny surgeon led start-up to a young, innovative Medical Devices Company which has developed and patented the innovative Spiral Laminar FlowTM (SLF) design technology. SLFTM technology restores the natural pattern of blood flow in vascular implants, improving the life of the implant, helping to prevent disease progression and improving outcomes for the patient. Our global platform technology is underpinned by 18 patent families and two recently filed new patents. We continue to build strong clinical evidence of a clear clinical superiority to current standard of care in the first two indications (Peripheral Vascular Grafts and Arteriovenous Access Grafts). Our business is focused on developing further clinical and health economic evidence and developing new products (stents and catheters) using the SLFTM technology platform within a growing $2.5bn market.

Cornerstone investors in place, investing £3.5m to-date. SLFTM observed and patent-protected by three Scottish Clinicians - Professor Peter Stonebridge, Professor Graeme Houston & John Dick. Company founded as Tayside Flow Technologies, registered in Scotland, then re-named Vascular Flow Technologies. First product approved with CE mark for Peripheral Vascular Grafts. Arteriovenous Access Grafts followed in June 2010. Cornerstone investors in place, investing £3.5m to-date. CEO Bill Allan appointed; strategy developed to prove commercial concept and build new product pipeline. US distributor model replaced with direct sales model; influential Clinical Advisory Board appointed.  New products launched in Europe and USA. Commercial case for SLFTM proven in the US. Strategic focus on Clinical Evidence Programme (CEP). Award of Horizon 2020 Phase 1 Grant for Peripheral Stent development.

The VFT Team ReDVA SECONDEES Angela Paterson: QA & RA Manager Bill Allan Craig Dunlop The VFT Team Barbara Bunger Kate Full Laurence Ryan Angela Paterson: QA & RA Manager Ann Verbrugghe: VP Market Development Caroline Toms: Admin Manager Rhonda McCrimmon: Assistant Accountant Martin Low: Office Assistant ReDVA SECONDEES Efstratios Kokkalis: University of Dundee Stephen Broderick: University of Limerick Leonard Brown: University of Limerick

Tour de table: Dundee Clinical Roles: Background ReDVA Patient Health Informatics Patient Questionnaire Basic Science: Haemodynamics in Clinical research MRI in ReDVA Clinical Trial Research: Ultrasound protocol MRI Protocol Trial Delivery

Dundee Team Expertise: Prof Houston, Stonebridge ( Clinical Vascular/Imaging) Prof Hoskins (Collaborator Edinburgh Ultrasound) Dr Gandy (MRI), Dr Ross (Ultrasound) Dr Aristokleous (Recruit Dundee) ESRs: Stratos Kokkalis ( Flow Rig/CFD - secondee to VFT) Deirdre Cassidy (MRI - secondee to Guerbet) Conor MacDonald (Physics – secondee Guerbet 2016)